Overall, these results validate the efficacy of CancerHubs predictions and establish TGOLN2 as a novel broad cancer hub with tumour suppressor-like properties and EFTUD2 as a novel MM hub with oncogenic properties. This evidence concerns the gene EFTUD2 and Miyoshi myopathy.